Scynexis Inc cash flow statement
In fiscal 2025, Scynexis Inc's operations generated −$5.3m of cash; it spent $0 on capital projects, leaving free cash flow of −$5.3m.
Cash flow statement
| Fiscal year | 2013Dec 2013 | 2014Dec 2014 | 2015Dec 2015 | 2016Dec 2016 | 2017Dec 2017 | 2018Dec 2018 | 2019Dec 2019 | 2020Dec 2020 | 2021Dec 2021 | 2022Dec 2022 | 2023Dec 2023 | 2024Dec 2024 | 2025Dec 2025 | LTMJun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash from operations | −4 | −9 | −25 | −29 | −25 | −28 | −38 | −49 | −55 | −80 | 60 | −24 | −5 | −13 |
| Depreciation and amortisation | 1 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 1 | 1 | 0 | — | — |
| Stock-based pay | 0 | 1 | 3 | 1 | 2 | 2 | 2 | 2 | 2 | 4 | 3 | 3 | 3 | 2 |
| Capital spending | 0 | 1 | 1 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | −5 | −10 | −25 | −29 | −25 | −29 | −38 | −49 | −55 | −80 | 60 | −24 | −5 | −13 |
| Free cash flow after stock pay | −5 | −11 | −28 | −31 | −26 | −31 | −40 | −52 | −57 | −84 | 58 | −27 | −8 | −16 |
| Shares issued | — | 62 | 41 | 28 | 10 | 32 | 46 | 91 | 39 | 47 | 0 | 0 | 0 | — |
| Quarter | 2024 Q3Sept 2024 | 2024 Q4Dec 2024 | 2025 Q1Mar 2025 | 2025 Q2Jun 2025 | 2025 Q3Sept 2025 | 2025 Q4Dec 2025 | 2026 Q1Mar 2026 | 2026 Q2Jun 2026 |
|---|---|---|---|---|---|---|---|---|
| Cash from operations | 1 | −10 | −7 | −7 | −9 | 18 | −8 | −15 |
| Depreciation and amortisation | 0 | 0 | — | — | — | — | — | — |
| Stock-based pay | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 |
| Capital spending | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Free cash flow | 1 | −10 | −7 | −7 | −9 | 18 | −8 | −15 |
| Free cash flow after stock pay | −0 | −11 | −8 | −8 | −9 | 18 | −9 | −15 |
| Shares issued | — | 0 | — | — | — | 0 | — | — |
Compare with peers
- Celularity Inc cash flow
- Cytomx Therapeutics, Inc. cash flow
- Proqr Therapeutics N.V. cash flow
- Janux Therapeutics, Inc. cash flow
- Keros Therapeutics, Inc. cash flow
Head to head: CELU vs SCYXCTMX vs SCYXPRQR vs SCYX
More: Biotechnology stocks compared, Health Care sector, rankings of US companies